Health and Healthcare

Alexion Pharmaceuticals, Inc. : ALXN

All ALXN Articles

307 Articles

Lee Jackson | Jul 20, 2015 at 8:50 AM EDT

4 Large Cap Biotech Stocks to Buy Before Earnings

A new research report from Cowen focuses on the top biotech stocks to buy before second-quarter earnings are reported.

Chris Lange | Jul 13, 2015 at 7:55 AM EDT

Short Sellers Back Off Big Biotech

24/7 Wall St. has reviewed the short interest in top biotech companies, without focusing on speculative companies.

Chris Lange | Jun 25, 2015 at 7:50 AM EDT

Short Sellers Get More Selective on Big Biotech

The short interest data are out for the June 15 settlement date, and overall, short interest in the selected biotech…

Chris Lange | Jun 20, 2015 at 9:35 AM EDT

5 Unusual Movers in the S&P 500

In the S&P 500, some stocks had significant moves this past week, and some were on exponential volume spikes as…

Chris Lange | Jun 13, 2015 at 9:05 AM EDT

5 Top Performers for the Past Week

24/7 Wall St. has put together a list of companies that have outperformed the market this past week.

Chris Lange | Jun 10, 2015 at 7:55 AM EDT

Short Sellers Lose Some Conviction Against Big Biotech

The May 29 short interest data have been compared with the previous figures, and for most of the selected biotech…

Chris Lange | May 28, 2015 at 8:25 AM EDT

Short Sellers Get Even More Ambitious Against Biotech Leaders

The short interest data are out for the May 15 settlement date. Biotech companies are considered a riskier group of…

Chris Lange | May 12, 2015 at 8:05 AM EDT

Short Sellers Start to Get Nervous on Biotech

The short interest data are out for the April 30 settlement date, and for most of the selected biotech stocks,…

Lee Jackson | May 7, 2015 at 8:30 AM EDT

Why These 4 Biotech Stocks Could Be the Next Buyout Targets

A new research note from SunTrust Robinson Humphrey mentions four stocks that they think could possibly get swept up in…

Lee Jackson | May 6, 2015 at 10:00 AM EDT

Huge Buyout Highlights 4 Deutsche Bank Biotech Focus Stocks

In a new report, Deutsche Bank acknowledges that while the industry has shown recent weakness, now may be just the…

Chris Lange | May 6, 2015 at 9:30 AM EDT

Is Alexion Grossly Overpaying for Synageva?

Biotech giant Alexion Pharmaceuticals announced Wednesday morning that it will acquire Synageva BioPharma.

Chris Lange | Apr 27, 2015 at 8:30 AM EDT

Short Sellers Become More Wary of Big Biotech

The short interest data are out for the April 15 settlement date. 24/7 Wall St. has reviewed the top biotech…

Chris Lange | Apr 13, 2015 at 8:35 AM EDT

Short Sellers Increase Their Bets Against Biotech Stocks

The March 31 short interest data have been compared with the March 13 figures, and for most of the selected…

Chris Lange | Mar 25, 2015 at 9:15 AM EDT

Major Biotech Is So-So for Short Sellers

The March 13 short interest data in top biotechs have been compared with the end of February figures, and across…

Chris Lange | Mar 18, 2015 at 2:10 PM EDT

How the Weaker Euro Is Impacting Biotech Earnings

Wells Fargo released a report Wednesday that considers the future of major biotech companies in relation to the weak euro.

1 … 14 15 16 17 18 … 21

Alexion Pharmaceuticals, Inc. : ALXN

All ALXN Articles

4 Large Cap Biotech Stocks to Buy Before Earnings

Short Sellers Back Off Big Biotech

Short Sellers Get More Selective on Big Biotech

5 Unusual Movers in the S&P 500

5 Top Performers for the Past Week

Short Sellers Lose Some Conviction Against Big Biotech

Short Sellers Get Even More Ambitious Against Biotech Leaders

Short Sellers Start to Get Nervous on Biotech

Why These 4 Biotech Stocks Could Be the Next Buyout Targets

Huge Buyout Highlights 4 Deutsche Bank Biotech Focus Stocks

Is Alexion Grossly Overpaying for Synageva?

Short Sellers Become More Wary of Big Biotech

Short Sellers Increase Their Bets Against Biotech Stocks

Major Biotech Is So-So for Short Sellers

How the Weaker Euro Is Impacting Biotech Earnings

MISL Investors: Watch the FY27 Budget Bill Before the Next Rally

Fed’s Rate Freeze Could Sting for Social Security Recipients

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s

MISL Investors: Watch the FY27 Budget Bill Before the Next Rally

Fed’s Rate Freeze Could Sting for Social Security Recipients

Alexion Pharmaceuticals, Inc. : ALXN

All ALXN Articles

4 Large Cap Biotech Stocks to Buy Before Earnings

Short Sellers Back Off Big Biotech

Short Sellers Get More Selective on Big Biotech

5 Unusual Movers in the S&P 500

5 Top Performers for the Past Week

Short Sellers Lose Some Conviction Against Big Biotech

Short Sellers Get Even More Ambitious Against Biotech Leaders

Short Sellers Start to Get Nervous on Biotech

Why These 4 Biotech Stocks Could Be the Next Buyout Targets

Huge Buyout Highlights 4 Deutsche Bank Biotech Focus Stocks

Is Alexion Grossly Overpaying for Synageva?

Short Sellers Become More Wary of Big Biotech

Short Sellers Increase Their Bets Against Biotech Stocks

Major Biotech Is So-So for Short Sellers

How the Weaker Euro Is Impacting Biotech Earnings

MISL Investors: Watch the FY27 Budget Bill Before the Next Rally

Fed’s Rate Freeze Could Sting for Social Security Recipients

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

Featured Reads

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s